Sontaga Manyana

Mr. Sontaga Manyana

Department of Virology, University of KwaZulu-Natal, Durban, South Africa
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
SMSontaga Manyana
Sontaga Manyana
LGLilishia Gounder
Lilishia Gounder
MPMelendhran Pillay
Melendhran Pillay
Justen ManasaJusten Manasa
Justen Manasa
KNKogieleum Naidoo
Kogieleum Naidoo
BCBenjamin Chimukangara
Benjamin Chimukangara
Affordable, sensitive, and scalable technologies are needed for monitoring antiretroviral treatment (ART) success with the goal of eradicating HIV-1 infection. This review discusses use of Sanger sequencing and next generation sequencing (NGS) methods for HIV-1 drug resistance (HIVDR) genotyping, focusing on their use in resource limited settings (RLS). Sanger sequencing remains the gold-standard method for detecting HIVDR mutations of clinical relevance but is mainly limited by high sequencing costs and low-throughput. NGS is becoming a more common sequencing method, with the ability to detect low-abundance drug-resistant variants and reduce per sample costs through sample pooling and massive parallel sequencing. However, use of NGS in RLS is mainly limited by infrastructure costs. Given these shortcomings, our review discusses sequencing technologies for HIVDR genotyping, focusing on common in-house and commercial assays, challenges with Sanger sequencing in keeping up with changes in HIV-1 treatment programs, as well as challenges with NGS that limit its implementation in RLS and in clinical diagnostics. We further discuss knowledge gaps and offer recommendations on how to overcome existing barriers for implementing HIVDR genotyping in RLS, to make informed clinical decisions that improve quality of life for people living with HIV.

1 June 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
BCBenjamin Chimukangara
Benjamin Chimukangara
RLRichard Lessells
Richard Lessells
BSBenn Sartorius
Benn Sartorius
LGLilishia Gounder
Lilishia Gounder
SMSontaga Manyana
Sontaga Manyana
RPRaveen Parboosing
Raveen Parboosing
In low-middle-income countries, increasing levels of HIV drug resistance (HIVDR) on second-line protease inhibitor (PI)-based regimens are a cause for concern given the limited drug options for third-line antiretroviral therapy (ART). We conducted a retrospective analysis of routine HIV-1 genotyping laboratory data from KwaZulu-Natal, South Africa, to describe the frequency and patterns of HIVDR mutations and their consequent impact on standardised third-line regimens. This was a cross-sectional analysis of all HIV-1 genotypic resistance tests conducted by the National Health Laboratory Service in KwaZulu-Natal (January 2015 to December 2016) for adults and adolescents (age ≥10 years) on second-line PI-based ART with virological failure. We assigned a third-line regimen to each record based on a national treatment algorithm and calculated the genotypic susceptibility score (GSS) for that regimen. Of 348 samples analysed, 287 (82.5%) had at least one drug resistance mutation (DRM) and 114 (32.8%) had at least one major PI DRM. Major PI resistance was associated with longer duration on second-line ART (aOR per 6-months = 1.11, 95% CI 1.04-1.19) and older age (aOR = 1.03, 95% CI 1.01-1.05). Of 112 patients requiring third-line ART, 12 (10.7%) had a GSS of <2 for the algorithm-assigned third-line regimen. One-third of people failing second-line ART had significant PI DRMs. A subgroup of these individuals had extensive HIVDR, where the predicted activity of third-line ART was suboptimal, highlighting the need for continuous evaluation of outcomes on third-line regimens and close monitoring for emergent HIV-1 integrase inhibitor resistance.

28 May 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
LGLilishia Gounder
Lilishia Gounder
ATAndrew Tomita
Andrew Tomita
RLRichard Lessells
Richard Lessells
SMSandrini Moodley
Sandrini Moodley
KFKerri-Lee Francois
Kerri-Lee Francois
BCBenjamin Chimukangara
Benjamin Chimukangara
South Africa rolled out dolutegravir (DTG) as first-line antiretroviral therapy (ART) in December 2019 to overcome high rates of pretreatment non-nucleoside reverse transcriptase inhibitor drug resistance. In the context of transition to DTG-based ART, this study spatiotemporally analysed detectable HIV viral loads (VLs) prior to- and following DTG rollout in public-sector healthcare facilities in KwaZulu-Natal (KZN) province, the epicentre of the HIV epidemic in South Africa. We retrospectively curated a HIV VL database using de-identified routine VL data obtained from the National Health Laboratory Service for the period January 2018 to June 2022. We analysed trends in HIV viraemia and mapped median log10 HIV VLs per facility on inverse distance weighted interpolation maps. We used Getis-Ord Gi* hotspot analysis to identify geospatial HIV hotspots. We obtained 7,639,978 HIV VL records from 736 healthcare facilities across KZN, of which 1,031,171 (13.5%) had detectable VLs (i.e., VLs ≥400 copies/millilitre (mL)). Of those with detectable VLs, we observed an overall decrease in HIV VLs between 2018 and 2022 (median 4.093 log10 copies/mL; 95% confidence interval (CI) 4.087–4.100 to median 3.563 log10 copies/mL; CI 3.553–3.572), p<0.01 (median test). The downward trend in proportion of HIV VLs ≥1000 copies/mL over time was accompanied by an inverse upward trend in the proportion of HIV VLs between 400 and 999 copies/mL. Moreover, specific coastal and northern districts of KZN had persistently higher VLs, with emergent hotspots demonstrating spatial clustering of high median log10 HIV VLs. The overall decrease in HIV VLs over time shows good progress towards achieving UNAIDS 95-95-95 targets in KZN, South Africa. The DTG-transition has been associated with a reduction in VLs, however, there is a need for pre-emptive monitoring of low-level viraemia. Furthermore, our findings highlight that specific districts will need intensified HIV care despite DTG rollout.

19 October 2024 in Viruses
Verified
Journal Article
Open access
PDF file
LGLilishia Gounder
Lilishia Gounder
AKAabida Khan
Aabida Khan
Justen ManasaJusten Manasa
Justen Manasa
RLRichard Lessells
Richard Lessells
ATAndrew Tomita
Andrew Tomita
BCBenjamin Chimukangara
Benjamin Chimukangara
HIV-1 drug resistance (HIVDR) impedes treatment and control of HIV-1, especially in high-prevalence settings such as KwaZulu-Natal (KZN) province, South Africa. This study merged routine HIV-1 genotypic resistance test (GRT) data with Geographic Information Systems coordinates to assess patterns and geographic distribution of HIVDR in KZN, among ART-experienced adults with virological failure. We curated 3133 GRT records generated between 1 January 2018 and 30 June 2022, which includes the early phase of dolutegravir (DTG) rollout, of which 2735 (87.30%) had HIVDR. Of the 2735, major protease, nucleoside, and non-nucleoside reverse transcriptase inhibitor mutations were detected in 41.24%, 84.97% and 88.08% of GRTs, respectively. Additional genotyping of HIV-1 integrase for 41/3133 (1.31%) GRTs showed that 17/41 (41.46%) had integrase strand transfer inhibitor resistance. Notably, of 26 patients on DTG with integrase genotyping, 9 (34.62%) had DTG-associated resistance mutations. Dual- or triple-class resistance was observed in four of every five GRTs. The odds of HIVDR increased significantly with age, with ≥60 years having 5 times higher odds of HIVDR compared to 18–29 years (p = 0.001). We identified geospatial differences in the burden of HIVDR, providing proof of concept that this could be used for data-driven public health decision making. Ongoing real-time HIVDR surveillance is essential for evaluating the outcomes of the updated South African HIV treatment programme.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
BCBenjamin Chimukangara
Benjamin Chimukangara
LGLilishia Gounder
Lilishia Gounder
MPMelendhran Pillay
Melendhran Pillay
SMSontaga Manyana
Sontaga Manyana
AKAabida Khan
Aabida Khan
KNKogie Naidoo
Kogie Naidoo
Background HIV drug resistance (HIVDR) remains a major threat to achieving sustainable viral suppression on antiretroviral therapy (ART). In South Africa, dolutegravir (DTG) is the preferred first-line ART backbone since its rollout in December 2019. Methods We curated HIVDR genotypic data obtained from the National Health Laboratory Service (NHLS) for ART-experienced patients with virological failure (i.e., consecutive viral loads ≥1,000 copies/mL) receiving HIV-care at public-sector health facilities in KwaZulu-Natal (KZN) province, South Africa. We estimated levels of HIVDR from genotypes processed between January 2018 and June 2022, and assessed temporal trends of HIVDR across 11 districts of KZN, prior to- and following DTG-rollout in South Africa. Results Of 4,069 genotypes curated, 3,511 (86.3% CI 85.2–87.3) had HIVDR mutations, with most resistance mutations occurring among adult females aged >15 years, p=0.01. Despite an annual decrease in protease inhibitor (PI)-specific mutations (p=0.0001), about one-third of genotypes had ≥3 drug-class resistance mutations, mainly nucleoside, and non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations. Only 50 genotypes had integrase resistance data, from which 9 (18.0%) had intermediate to high-levels of resistance to DTG. Overall, rural districts had fewer HIVDR genotypes (598/4069, 15%) but with higher HIVDR prevalence (88.1% CI 85.3–90.6) compared to densely populated peri-urban and urban districts. Conclusion Six in every seven genotypes from patients with virologic failure had HIVDR mutations despite DTG-rollout, with persistent NNRTI resistance. Thus, whilst introduction of DTG is expected to alleviate HIVDR burden, a sub-population of people may not fully benefit from DTG-use due to multi-drug resistance, at which point PI-based ART is warranted. Higher proportions of HIVDR in rural districts and among adult women, highlight regions and individuals needing priority HIV care. Overall, these findings urge strengthening of HIV services in public healthcare systems to ensure sustainable DTG-use in first-line and subsequent ART regimens.